ANI Pharmaceuticals, Inc.
General ticker "ANIP" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.6B (TTM average)
ANI Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 6.0%.
Estimated limits based on current volatility of 1.9%: low 79.02$, high 82.16$
Factors to consider:
- Total employees count: 642 (+7.0%) as of 2023
- US accounted for 98.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Commercialization failure, Market competition, Manufacturer dependency, Regulatory and compliance, Manufacturing disruptions
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [65.65$, 102.46$]
- 2026-12-31 to 2027-12-31 estimated range: [65.73$, 103.74$]
Financial Metrics affecting the ANIP estimates:
- Negative: with PPE of 10.3 at the end of fiscal year the price was high
- Positive: 6.62 < Operating cash flow per share per price, % of 11.35
- Positive: Industry inventory ratio change (median), % of 0.12 <= 0.28
- Positive: 7.57 < Operating profit margin, % of 9.20
- Positive: -4.39 < Investing cash flow per share per price, % of -2.10
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 5.16
- Positive: 19.19 < Shareholder equity ratio, % of 37.54 <= 42.57
Short-term ANIP quotes
Long-term ANIP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $486.82MM | $619.72MM | $882.98MM |
| Operating Expenses | $439.85MM | $619.14MM | $771.89MM |
| Operating Income | $46.97MM | $0.58MM | $111.09MM |
| Non-Operating Income | $-27.10MM | $-22.80MM | $-15.30MM |
| Interest Expense | $26.94MM | $17.60MM | $20.06MM |
| R&D Expense | $34.29MM | $44.58MM | $51.66MM |
| Income(Loss) | $19.87MM | $-22.21MM | $95.79MM |
| Taxes | $1.09MM | $-3.69MM | $17.45MM |
| Net Income(Loss)* | $18.78MM | $-18.52MM | $78.34MM |
| Stockholders Equity | $432.75MM | $403.68MM | $540.72MM |
| Inventory | $111.20MM | $136.78MM | $143.07MM |
| Assets | $904.42MM | $1,284.47MM | $1,440.38MM |
| Operating Cash Flow | $118.96MM | $64.02MM | $185.22MM |
| Capital expenditure | $18.51MM | $16.95MM | $34.32MM |
| Investing Cash Flow | $-18.51MM | $-404.72MM | $-34.32MM |
| Financing Cash Flow | $67.44MM | $264.94MM | $-9.94MM |
| Earnings Per Share** | $1.04 | $-0.96 | $3.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.